• Home >
  • Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

17-Jul-2015  /  Research Code: D757-00-03-00-00  /  SKU: HC02733-GL-TA_19627  /  
Region: Global

USD 250.00

* Required Fields

USD 250.00

PAY BY INVOICE

Be the first to review this product

This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.

Table of Contents

Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in EuropeIn This Issue1. DRUG FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY TREATMENT RECEIVES ORPHAN DRUG DESIGNATION2. NON-VIRAL CFTR-BASED GENE THERAPY FOR CYSTIC FIBROSIS PATIENTS3. BREAST CANCER DIAGNOSTIC TEST IN EUROPE4. RECENT PATENTS IN GENETIC TESTS IN THE EUROPEAN UNION5. TECHVISION 2015




Keyword1

Keyword2

Keyword3

Related Research

Why Now is The Time for Interoperable Healthcare Solutions?

Release Date : 05-Jul-18

Region : Global

2018 Top Technologies in Health & Wellness

Release Date : 30-Apr-18

Region : Global

Global Laboratory Products Purchasing Trends, 2017–2018

Release Date : 15-Feb-18

Region : Global

Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020

Release Date : 06-Feb-18

Region : Global

Emerging Sensor Technologies Transforming Medical Diagnostics

Release Date : 29-Dec-17

Region : Global

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Vision & Strategy

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Brand & Demand

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Technology & IP

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

Global Prespective

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.